Cannabis

EQS-News: Cannovum Cannabis AG: Federal Council confirms cannabis legalization as of April 1, 2024, positive growth opportunities in Europe's largest consumer market

Retrieved on: 
Wednesday, April 10, 2024

Cannovum Cannabis AG: Federal Council confirms cannabis legalization as of April 1, 2024, positive growth opportunities in Europe's largest consumer market

Key Points: 
  • Cannovum Cannabis AG: Federal Council confirms cannabis legalization as of April 1, 2024, positive growth opportunities in Europe's largest consumer market
    The issuer is solely responsible for the content of this announcement.
  • Cannovum Cannabis AG: Federal Council confirms cannabis legalization as of April 1, 2024, positive growth opportunities in Europe's largest consumer market
    Cannovum Cannabis AG (stock exchanges Frankfurt/Xetra, Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A37FUP2) welcomes the legalization of cannabis in Germany confirmed today by the Federal Council.
  • This will provide new impetus for a billion-euro market in Europe's largest economy in the coming years.
  • Cannovum Cannabis AG plans to generate significant sales through offers for existing and emerging cannabis clubs.

Hemp, Inc. Welcomes USDA Approval of GMO Hemp Strain – A Step Forward in Cannabis Biotechnology

Retrieved on: 
Tuesday, April 9, 2024

The newly approved GMO hemp variety, a breakthrough by the University of Wisconsin, is known as "Badger G".

Key Points: 
  • The newly approved GMO hemp variety, a breakthrough by the University of Wisconsin, is known as "Badger G".
  • Hemp, Inc. recognizes the pivotal role of biotechnology in the evolution of the cannabis industry.
  • This innovative strain stands to solve a pivotal problem in the hemp cultivation sector: regulatory compliance regarding THC levels.
  • This milestone in GMO hemp sets the stage for Hemp, Inc. to continue its commitment to innovation, sustainability, and legal compliance within the industry.

BC Bud Union Grows

Retrieved on: 
Tuesday, April 9, 2024

This landmark organizing drive represents a significant milestone for cannabis workers across BC.

Key Points: 
  • This landmark organizing drive represents a significant milestone for cannabis workers across BC.
  • Joining Trees Cannabis locations in Victoria, which first organized with UFCW 1518 in 2021, these workers join the growing BC Budtenders Union.
  • The BC Budtenders Union, a division of UFCW 1518, formed in 2020 when cannabis workers in Victoria united as the first unionized dispensaries in Canada.
  • “We love what we do, we are good at it, and we deserve to thrive in the cannabis industry.”
    The BC Budtenders Union continues to fight for the fairness and respect that BC’s cannabis workers deserve.

Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results

Retrieved on: 
Tuesday, April 9, 2024

ET Today

Key Points: 
  • ET Today
    NEW YORK and LEAMINGTON, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today reported financial results for its third quarter ended February 29, 2024.
  • Beverage-alcohol gross profit increased 89% to $18.9 million in the third quarter from $10.0 million in the prior year quarter.
  • Completed Canadian cannabis business cost reduction plan launched during fiscal year 2022 and international cannabis business plan launched during fiscal year 2023.
  • For its fiscal year ending May 31, 2024, the Company is now guiding to an Adjusted EBITDA target of $60 million to $63 million.

HYTN Welcomes Health Canada for Audit to Enhance GMP Capabilities

Retrieved on: 
Tuesday, April 9, 2024

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, “HYTN” or “The Company”), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis, welcomed Health Canada’s conduct of a Drug Establishment License (DEL) audit.

Key Points: 
  • VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, “HYTN” or “The Company”), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis, welcomed Health Canada’s conduct of a Drug Establishment License (DEL) audit.
  • The audit, which aims to expand the Company's Good Manufacturing Practices (GMP) capabilities, follows the recent achievement of GMP certification for HYTN's Kelowna production facility by Australia's Therapeutic Goods Administration (TGA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) standard.
  • Securing a DEL will enhance HYTN's current GMP manufacturing capabilities, facilitating the development and sale of additional compounds and product variations.
  • HYTN has demonstrated its ability to manufacture these products according to GMP guidelines.

Brain & Behavior Research Foundation Awards Distinguished Investigator Grants Valued at $1 Million to 10 Scientists Pursuing Innovative Mental Health Research

Retrieved on: 
Thursday, April 4, 2024

New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.

Key Points: 
  • New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.
  • By funding transformative research focused on new ways to prevent, diagnose, and treat psychiatric disorders, our Distinguished Investigator Grants are encouraging established scientists to continue advancing our understanding of mental illness and disorders of brain and behavior,” says Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation.
  • The ground-breaking work of the Distinguished Investigator Grant recipients will bring hope and healing to people and families impacted by mental illness.
  • We applaud these scientists for their extraordinary dedication, innovation, and leadership.”
    Recipients of the Distinguished Investigator Grants are full professors at research institutions in the United States and abroad.

RC Show 2024 Releases Sneak Peek at its Dynamic Speaker Lineup

Retrieved on: 
Wednesday, April 3, 2024

Learn about the latest innovations, valuable insights, current issues, and discover solutions that will help support the industry going forward.

Key Points: 
  • Learn about the latest innovations, valuable insights, current issues, and discover solutions that will help support the industry going forward.
  • RC Show gives attendees access to world-class educational and interactive speaker sessions, workshops and panels over three days, across six stages.
  • Here’s a taste of this year’s programming highlights and who RC Show is bringing to the table:
    Kick off the RC Show Speaker Series with a bang.
  • Catch her bartending skills live and up-close on the RC Pop-Up Stage April 9, 11 a.m.-1 p.m.

Lifeist Initiates Restructuring Proceedings for CannMart Labs Inc.

Retrieved on: 
Wednesday, April 3, 2024

TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced that it has commenced restructuring proceedings pursuant to the Bankruptcy and Insolvency Act for one of its wholly owned subsidiaries, CannMart Labs Inc. (”CannMart Labs”).

Key Points: 
  • TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced that it has commenced restructuring proceedings pursuant to the Bankruptcy and Insolvency Act for one of its wholly owned subsidiaries, CannMart Labs Inc. (”CannMart Labs”).
  • The restructuring of CannMart Labs is part of a broader strategic initiative to enhance the company's operational effectiveness while maintaining its commitment to innovation and growth.
  • "Following a thorough financial and strategic review, we believe that it is in the best interest of shareholders for CannMart Labs alone to enter into restructuring proceedings in order to address its obligations and contributions to Lifeist's balance sheet," said Meni Morim, CEO of Lifeist.
  • The decision to initiate restructuring proceedings for CannMart Labs underscores Lifeist's dedication to adaptability and resilience in navigating the dynamic landscape of the cannabis industry.

Tilray Medical Announces New Scientific Publication on Age-Related Patterns of Medical Cannabis Use

Retrieved on: 
Wednesday, April 3, 2024

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada. The new study was derived from the Canadian Cannabis Patient Survey (CCPS) 2021, comprised of 2,697 patients and focused primarily on older patients with a mean age of 54.3. This study presents to the medical and scientific community the consumption trends observed in patients and the self-reported impacts from medical cannabis in alleviating the patients’ primary symptoms.

Key Points: 
  • Tilray Led Study Shows Chronic Pain, Arthritis, Anxiety, and Insomnia as Primary Illnesses and Symptoms for Medical Cannabis Use
    NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada .
  • This study presents to the medical and scientific community the consumption trends observed in patients and the self-reported impacts from medical cannabis in alleviating the patients’ primary symptoms.
  • The Age-related Patterns of Medical Cannabis Use study finds that older patients comprise a growing subset of medical cannabis patients.
  • José Tempero, Tilray’s Medical Director, said, "Our role in this initiative exemplifies our commitment to medical research, leading us one step closer to unlocking the full therapeutic potential of medical cannabis."

HYTN Provides Corporate Update, Outlines New Global Direction

Retrieved on: 
Wednesday, April 3, 2024

HYTN is announcing two strategic commercial initiatives underscoring the company’s commitment to leading the GMP-certified cannabis products industry.

Key Points: 
  • HYTN is announcing two strategic commercial initiatives underscoring the company’s commitment to leading the GMP-certified cannabis products industry.
  • HYTN expects to commercialize both business to business and wholesale opportunities under this initiative.
  • Additionally, HYTN aims to unlock global markets for established cannabis brands by leveraging the company's regulatory compliance, supply chain capabilities and Quality Management System.
  • The authorization to process cannabis flower into pharmaceutical-grade products for export provides a significant advantage in a market actively seeking GMP-certified cannabis."